GW's senior management team comprises highly experienced pharmaceutical professionals with the necessary skills and expertise to guide new medicines through from early stage research to global clinical development, regulatory approval, commercial manufacture and distribution.
Mrs Emery has over 25 years management experience in the pharmaceutical and related industries, including both large multinational organisations and small entrepreneurial companies. Before working with GW, Mrs Emery was Group Quality Assurance Manager with Scotia Holdings PLC, where she was responsible for the creation and management of quality systems, that were involved in inspections and approval by both US and UK Regulatory Authorities. Prior to that she was Technical Affairs Manager for Sterling-Winthrop, now Sanofi-Synthelabo, where she was responsible for a variety of technical projects, including preparation of drug master files and Regulatory support.
Mrs Emery has particular experience with other natural products developed for use as pharmaceuticals, acting as the Expert in European regulatory dossiers. She has also been involved in technical transfer of product from R & D through to commercial manufacturing and distribution.
Mrs Emery is a Qualified Person, a Fellow of the Royal Society of Chemistry and a member of TOPRA (The Organisation for Professionals in Regulatory Affairs)
Mr Etges has been with GW Pharmaceuticals since 2001 and has worked in the pharmaceutical industry for over 17 years, 13 years of which have been in Pharmacovigilance. Prior to joining GW, Mr Etges worked for Ethical Pharmaceuticals/Elan Transdermal Technologies in Cambridgeshire as Technical Services Manager for marketed products including controlled drug substances.
Mr Etges has been responsible for managing and expanding a successful and compliant global system and team for Pharmacovigilance/Drug Safety for over 9 years. He completed an MSc in Pharmacovigilance in 2012 and is responsible as the Qualified Person for Pharmacovigilance.
Julian Gangolli serves as President, North America since his appointment in June, 2015. Mr. Gangolli has more than two decades of senior management experience with large pharmaceutical, specialty pharmaceutical, and start‐up biotechnology companies.
Prior to joining GW, Mr Gangolli, was, from 2004 until April 2015, President of the North American Pharmaceutical division of Allergan Inc, with responsibility for a 1,400-person integrated commercial operation with sales exceeding $3.8 billion in 2014. As a Corporate Vice President and member of the Executive Committee, Allergan’s most senior leadership team overseeing worldwide operations, Mr Gangolli was an integral part of the executive management team that transformed Allergan into one of the leading specialty pharmaceutical companies in the U.S. Prior to Allergan, Mr Gangolli was Vice President, Sales and Marketing at VIVUS, Inc. where he established from inception a fully functioning commercial operation. Prior to VIVUS, Mr Gangolli held roles at Syntex Pharmaceuticals, Inc. and Ortho-Cilag Pharmaceuticals Ltd. in the UK.
Mr. Gangolli was raised in the UK, received a BSc (Honors) in Applied Chemistry from Kingston University in England, and is a U.S. citizen.
Dr Gibson more than 25 years experience in pharmaceutical development, working with new chemical entities and generic products, in both contract research and established pharmaceutical companies.
Prior to joining GW Pharmaceuticals Dr Gibson was Director of Scientific Services for Elan Transdermal Technologies (UK) Limited (previously Ethical Pharmaceuticals Ltd) and was responsible for a wide range of technical and scientific activities for the company, including formulation development, analytical services, bioanalysis and information technology services.
Dr Gibson was co-founder of Bioanalytical Research Ltd in 1985, a contract research company specialising in bioanalysis for the pharmaceutical industry, which was sold in 1990 to Ethical Pharmaceuticals Ltd.
Mr. Haynes is a veteran of the pharmaceutical industry with over 20 years of product pre-launch, launch and lifecycle management experience within a variety of pharmaceutical organizations of all sizes and geographies. In addition, Mr. Haynes has particular experience across a variety of orphan disease areas and with scheduled drugs.
As well as having significant breadth in organizational experience, Mr. Haynes has held positions in a wide range of commercial functions including sales, market research, medical affairs, marketing, country general management, European management and most recently as Vice President Global Commercial Operations (with a focus on US pre-launch planning) at Swedish Orphan Biovitrum. Prior to Biovitrum, Mr. Haynes held senior-level roles in commercial operations at UCB Pharma, Sobi and Bristol- Myers Squibb.
Manuel Loureda has 25 years’ experience in the pharmaceutical manufacturing industry. He graduated as a Chemical Engineer in 1982 and went on to perform three years post graduate research at the British Gas London Research Station working on acid gas removal and desorption.
He then joined US multinational Merck at the MSD manufacturing facility in the UK. During his 20 year career with Merck he held positions in process development, capital project management, engineering management, health & safety and manufacturing. He was a project director on a £50M new product introduction with project responsibility from conception through to process validation on a new state of the art facility.
Manuel joined Genzyme, now a Sanofi company, in 2006 as Operations director at their manufacturing facility near Cambridge. He was responsible for all Manufacturing on site, Facilities, Engineering as well as Environmental, Health & Safety. He led a £22M manufacturing facility expansion and new product introduction followed by a successful FDA inspection.
Ms Mead is an attorney specialising in health care law. For eleven years prior to joining GW, she served as Legal Counsel to the California Medical Association, the largest state medical association in the United States. During that time, she has developed special expertise in the legal and regulatory issues surrounding the production of medicinal cannabis. She has also prepared detailed guidelines on the subject for the medical profession, which have been widely adopted throughout that State and the US generally.
Prior to joining the California Medical Association, Ms Mead served as a litigator for Morrison & Foerster and was previously a law professor at Arizona State University College of Law.
Professor Pertwee joined GW as Director of Pharmacology in March 2002, and at the same time has retained his position as Professor of Neuropharmacology at the University of Aberdeen. He is one of the world's leading cannabinoid scientists, having researched this area for over 40 years, and is the author of over 240 publications. He is frequently consulted on the therapeutic potential of cannabis and cannabinoids by parliamentary committees and leading medical organisations and has been involved with both the 1998/99 Royal Pharmaceutical Society working party on cannabis and the House of Lords Science & Technology Committee investigation into cannabis.
It was collaborative research carried out in the early 1990s by Professor Pertwee and Professor Raphael Mechoulam in Jerusalem that first led to the discovery of endocannabinoids.
Professor Pertwee is Co-chair of the International Union of Pharmacology (IUPHAR) Subcommittee on Cannabinoid Receptors, has served as chairman of the International Association for Cannabis as Medicine (IACM; 2005-2007), as President of the International Cannabinoid Research Society (ICRS; 1997-1998; 2007-2008) and is currently ICRS International Secretary and a member of the IACM board of directors. He was the recipient of the 2002 Mechoulam Award “for his outstanding contributions to cannabinoid research” and in 2005 was recognised as an “ISI Highly Cited Researcher”. In December 2011, Professor Pertwee became the 19th recipient of the Wellcome Gold Medal. Of the previous recipients, three have been Nobel Prize winners and 16 have been Fellows of the Royal Society.
Before joining GW as its first employee in 1998, Dr Potter had twenty three years research experience as a horticulturalist and agronomist. He also managed security at the research laboratory complex of a multinational company for three years.
Dr Potter gained his research PhD in 2009 at Kings College London, having studied the pharmacognosy of Cannabis sativa. He is a Chartered Biologist, a Fellow of the Society of Biology, a Fellow of the Linnean Society and a Chartered Member of the Institute of Occupational Safety and Health.
Dr Potter regularly acts as an expert witness and police advisor on cannabis issues and, in recognition of this service, he received a commendation from ACPO (The Association of Chief Police Officers) in 2007 and 2009.
Mr Richard Potts is the Clinical Operations Director at GW Pharmaceuticals, where he brings more than 20 years of experience in pharmaceutical development. He is responsible for leading all aspects of the company's clinical research operations, including the implementation and management of global clinical trials (Phases 1-4). Mr Potts has oversight of Medical Writing, Biometrics (Clinical Statistics and Data Management), Clinical Monitoring, Clinical Programme Management and Clinical Coordination. He also has oversight of the company's alliances with contract research organisations.
Prior to joining GW Pharmaceuticals in 2001, Mr Potts spent seven years working for Napp Pharmaceuticals in the UK, where his principal responsibilities and achievements included the conception, design and successful execution of global clinical trials and prior to this, he spent two years working for Astra Zeneca in Sweden. Mr Potts holds a BSc. degree in Chemistry from the University of Lancaster, UK.
Dr Robson is an expert in the therapeutic potential of cannabis and cannabinoids. In 1996 he was commissioned by the Department of Health to carry out a critical review of the relevant scientific literature and in 1998 was called on to submit both written and verbal evidence to the House of Lords Science & Technology Committee investigation into cannabis.
Prior to joining the Group, Dr Robson was for the previous ten years, a Consultant Psychiatrist in Oxford and Senior Clinical Lecturer in the Oxford University Department of Psychiatry. In addition to his duties as Director of the Cannabinoid Research Institute, Dr Robson retains the position of Senior Research Fellow in the Oxford University Department of Psychiatry.
Prior to taking up his psychiatry posts at Oxford, Dr Robson worked for eight years within the pharmaceutical industry, initially as a clinical pharmacologist and then as Director of Clinical Research at Wyeth Laboratories.
Mr. Schultz has close to 25 years of experience in investor relations, financial communications and media relations. Most recently, from January 2011 to March 2013, Mr. Schultz served as Senior Director of Investor Relations and Corporate Communications at Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health.
Prior to Amarin, Mr. Schultz served as the Executive Director of the Jackson Hole Center for the Arts, a not-for-profit organization aimed at promoting artistic creativity and education. Mr. Schultz’s extensive investor relations and corporate communications experience also includes senior-level roles at Acusphere, Shareholder.com (a Nasdaq company), Manufacturer’s Services Limited, Wang Global and The ForeFront Group. Mr. Schultz holds a B.A. degree from St. Lawrence University.
Renuka has 23 years’ experience working in the Pharmaceutical Industry. Over these years Renuka has gained experience in Gastroenterology, Dermatology, Respiratory, Ophthalmology, Rheumatology and Multiple Sclerosis therapies. She has worked in partnership with the NHS over these years and been a part of the constant transition of the NHS gaining valuable insight into the relationship between Pharmaceutical companies and the NHS.
With her past sales and commercial experience Renuka joined GW in January 2012 to manage Sativex globally. This involves alliance management with our marketing partners’, key opinion leader development for the brand and development of the additional value of Sativex versus comparators for future indications. Renuka works closely with all our marketing partners for Sativex launches and to facilitate reimbursement across the globe.
Renuka is a member of the Association of the British Pharmaceutical Industry and works within their guidelines.
Dr. Sommerville is a board-certified neurologist and joins GW with a significant record of achievement including twenty-three years of experience in the pharmaceutical industry. He has had senior roles at UCB/Schwarz Pharma and Abbott Laboratories where he led clinical and regulatory programs in epilepsy and other neurological product development initiatives including NDA submissions to FDA and EMEA for multiple compounds.
Most recently, Dr. Sommerville served as Vice President of Clinical Sciences at Pfizer, Inc. where he was Global Clinical Lead for opioids and led a team of physicians and scientists in the development of abuse-deterrent opioids. He also has led teams in multiple medical and scientific areas including, but not limited to, indications of complex partial seizures, basic and rapid infusion of an intravenous anti-convulsant, painful diabetic neuropathy, migraine prophylaxis, Parkinson’s disease, bipolar disorder, personality disorders, and schizophrenia.
Dr. Sommerville has made major contributions to over twenty NDA submissions for both the FDA and EMEA and is recognized as an authority in drug development, especially anti-epileptic drugs, pain, and abuse-deterrent opioids.
Mr Stott has been with GW since January 2001 and has twenty-two years experience in the pharmaceutical industry covering a wide range of new chemical entities, biotechnology products and plant-based medicines, with 20 years experience of clinical development and 14 years experience of preclinical development.
Prior to joining GW, Mr Stott was Clinical Programme Manager & International Project Leader at Napp Pharmaceuticals Ltd, leading an international joint development programme of a plant-based medicine. Prior to this he was Clinical Projects Manager at the plant medicines company Phytopharm plc between 1996 and 1999, managing clinical and pre-clinical development programmes. Mr Stott also has experience gained at Astra Zeneca, Schering-Plough Limited, Genzyme (UK) Limited and Alpha Therapeutics Limited (now Grupo Grifols).
Mrs Thompson has been with GW since 1999 and has worked in the field of management of regulatory affairs for over 14 years. Before joining GW she worked at Novartis as Manager, Regulatory Affairs, in the veterinary products division. Prior to entering the life sciences industry, Mrs Thompson worked for 10 years in the agricultural arena, including chairing working parties in Brussels and London involved in feed additive legislation.